Nanobiotix (PAR:NANO.PA) inked a non-dilutive financial deal with the European Investment Bank last week to support the development of its nanoparticle-based cancer therapies.
The Paris, France-based company said it landed a five-year loan to borrow up to €40 million ($46.7 million) contingent upon a set of performance milestones.
Get the full story at our sister site, Drug Delivery Business News.
The post Nanobiotix inks $47m financing to support nanomedicine development appeared first on MassDevice.